subject: Pipeline And Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed By Generic Erosi [print this page] Introduction Introduction
Estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a decline to $4.2 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.
Scope
*Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
*Assessment of key drug classes for allergic rhinitis, with analysis of impacting events and a 10 year sales forecast split by indication
*In-depth discussion of the role of immunotherapy in allergic rhinitis, with analysis of developments, regulations, and pipeline products
*Interactive patient-based forecasts of 3 immunotherapy products, with a discussion of their relative strengths and weaknesses
Highlights
Estimates 2009 allergic rhinitis sales in the seven major markets of $5 billion. This is forecast to drop to $4.2 billion in 2019, driven by the entrance of cheap generics, most notably in the US. Oral antihistamines are the more vulnerable to generic erosion, while nasal corticosteroids are partially protected by their device.
Reformulation of molecules and combinations are common, but timing is key. In 2009, Mercks Clarinex (desloratadine) had a quarter of Claritins (loratadine) peak sales, having launched after generics. Meda Pharmas azelastine follow-on has seen more success launching prior to patent expiry and Meda Pharma is now combining the drug with a steroid.
Changing regulations are driving development of immunotherapies, with large-scale development programs seen in recent years. While immunotherapy is expected to remain a niche market, significant growth is forecast. Two sublingual grass tablets, Grazax (ALK-Abell) and Oralair (Stallergnes) forecast to have sales of $250m in the US and EU by 2019.
Reasons to Purchase
*Understand allergic rhinitis market trends, including life cycle management, current sales, and a 10 year sales forecast of symptomatic treatments
*Gain insight into the immunotherapy market and access patient based forecasts of three key immunotherapy products, with interactive assumptions
*Use analysis of key companies in the market and see how allergic rhinitis contributes to total brand sales
Table of Contents :
OVERVIEW 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Immunology & Inflammation pharmaceutical analysis team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the allergic rhinitis market 3
Related reports 4
Upcoming related reports 4
TABLE OF CONTENTS 4
1. PATIENT AND MARKET OVERVIEW 5
Key findings 5
Market definition for this report 6
Sales split by indication 6
Over- the-counter market impact 8
Patient potential 9
Disease definition 9
Patient segmentation 10
Seven major markets 11
Rest of World 17
Prevalence of key allergic diseases 18
Allergens 19
Market overview 20
Opportunities and threats 22
Seven major market opportunities and threats 23
Opportunity 1 - over-the-counter (OTC) status may extend revenue after patent expiry 23
Opportunity 2 - increasing awareness of allergic rhinitis 24
Opportunity 3 - allergy seasons start earlier, last longer and are more intense 25
Threat 1: governments reductions in healthcare expenditure through controlling pricing and reimbursement 26
Threat 2: key patent expires will change the allergic rhinitis market 27
US: opportunities and threats 27
Allergic rhinitis market overview 27
US formulary tier status for leading brands 28
Opportunities 30
Opportunity 1 - the OTC market is becoming more important in the US 30
Opportunity 2 - direct-to-consumer (DTC) advertising of prescription medicines highly influential in the US 31
Threats 32
Threat 1 - reimbursement controls reduce healthcare expenditure in the US 32
Threat 2 - generic entry to shrink the allergic rhinitis market 32
Japan: opportunities and threats 33
Allergic rhinitis market overview 33
Opportunity 1 - new regulation of OTC drugs 34
Opportunity 2 - no gatekeeper system 35
Threat 1 - generic influence to grow 35
Threat 2 - long approval process dampens access to Japanese market 35
EU: opportunities and threats 36
Allergic rhinitis market overview 36
Opportunity 1 - generic markets less developed than in the US 37
Threat 1 - cost containment policies to impact drug prices 38
